Contents

Highlights of This Issue 5915

SPECIAL FEATURES

CCR Translations

5917 Braking Bad: Blockade of Inhibitory Pathways Improves Interleukin-15 Therapy William E. Carson III

5920 Toward a Better Understanding of Race and Cancer Otis W. Brawley

CCR Drug Updates

5923 Pazopanib in Renal Cell Carcinoma James E. Ward and Walter M. Stadler

Molecular Pathways

5928 Hypoxia and Hypoxia-Inducible Factors: Master Regulators of Metastasis Xin Lu and Yibin Kang

5936 Targeting RET Receptor Tyrosine Kinase Activation in Cancer John E. Phay and Manisha H. Shah

Review

5942 Resveratrol: Challenges in Translation to the Clinic — A Critical Discussion Lalita Subramanian, Sherry Youssef, Saswati Bhattacharya, Jason Kenealey, Arthur S. Polans and Paul R. van Ginkel

5950 Striving to Improve Outcomes in Oncology: Unmet Expectations in a Complex Disease Susan E. Bates

5951 Translating Clinical Trials into Meaningful Outcomes Patricia M. LoRusso, Lowell E. Schnipper, David J. Stewart, Scott A. Boerner, Steven D. Averbuch and Walter Wolf

5956 Making the Investigational Oncology Pipeline More Efficient and Effective: Are We Headed In the Right Direction? Patricia M. LoRusso, Aparna B. Anderson, Scott A. Boerner and Steven D. Averbuch

5963 Evaluating Patient-Centered Outcomes in the Randomized Controlled Trial and Beyond: Informing the Future with Lessons from the Past Christopher M. Booth

5972 Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much? Tito Fojo and David R. Parkinson

5981 Explaining Marginal Benefits to Patients, When “Marginal” Means Additional but Not Necessarily Small Thomas J. Smith and Bruce E. Hillyer


5997 The Impact of Insurance on Access to Cancer Clinical Trials at a Comprehensive Cancer Center Justin F. Klamerus, Suanna S. Bruinooge, Xiaobu Ye, Mandi L. Klamadas, Dorothy Damron, Dina Lansey, John C. Lowery, Luis A. Diaz Jr., Jean G. Ford, Norma Kanarek and Charles M. Rudin

5997 Value and Cancer Care: Toward an Equitable Future Lowell E. Schnipper, Neal J. Meropol and Dan W. Brock

The Journal of Clinical and Translational Research iii www.aacrjournals.org

Downloaded from clincancerres.aacrjournals.org on April 13, 2017. © 2010 American Association for Cancer Research.
HUMAN CANCER BIOLOGY

6009  IQGAP1 Plays an Important Role in the Invasiveness of Thyroid Cancer
Zhi Liu, Dingxie Liu, Ermal Bojdani, Adel K. El-Naggar, Vasily Vasko and Mingzhao Xing

CANCER THERAPY: PRECLINICAL

6019  Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model
Ping Yu, Jason C. Steel, Meili Zhang, John C. Morris and Thomas A. Waldmann

6029  Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma
Saadia A. Aziz, Lucia B. Jilaveanu, Christopher Zito, Robert L. Camp, David L. Rimm, Patricia Conrad and Harriet M. Kluger

6040  The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations

IMAGING, DIAGNOSIS, PROGNOSIS

6083  Genotypic Profiling of 452 Choroidal Melanomas with Multiplex Ligation-Dependent Probe Amplification
Bertil Damato, Justyna A. Dopierala, Sarah E. Coupland

6093  Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer

6100  Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study

6111  A Combination of Serum Markers for the Early Detection of Colorectal Cancer
Norbert Wild, Herbert Andres, Wolfgang Rollinger, Friedemann Krause, Peter Dilba, Michael Tacke and Johann Karl

CANCER THERAPY: CLINICAL

6122  CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
Mark E. Dudley, Colin A. Gross, Michelle M. Langhan, Marcos R. Garcia, Richard M. Sherry, James C. Yang, Giao Q. Phan, Udai S. Kammula, Marybeth S. Hughes, Deborah E. Citrin, Nicholas P. Restifo, John R. Wunderlich, Peter A. Prieto, Jenny J. Hong, Russell C. Langan, Daniel A. Zlott, Kathleen E. Morton, Donald E. White, Carolyn M. Laurencot and Steven A. Rosenberg

6132  Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAh-009 in Patients with Mesothelin-Expressing Cancers
Raffit Hassan, Steven J. Cohen, Martin Phillips, Ira Pastan, Elad Sharon, Ronan J. Kelly, Charles Schweizer, Susan Weil and Daniel Laheru
Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine


Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study

Denis C. Talbot, Malcolm Ranson, Joanna Davies, Michael Lahn, Sophie Callies, Valérie André, Sunil Kadam, Michael Burgess, Christopher Slapak, Anna L. Olsen, Peter J. McHugh, Johann S. de Bono, Julian Matthews, Azeeem Saleem and Patricia Price

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

Monika Graeser, Afshan McCarthy, Christopher J. Lord, Kay Savage, Margaret Hills, Janine Salter, Nicholas Orr, Marina Parton, Ian E. Smith, Jorge S. Reis-Filho, Mitch Dowsett, Alan Ashworth and Nicholas Turner

Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer

Song Yao, William E. Barlow, Kathy S. Albain, Ji- Yeob Choi, Hua Zhao, Robert B. Livingston, Warren Davis, James M. Rae, J- Tien Yeh, Laura F. Hutchins, Peter M. Ravdin, Silvana Martino, Alan P. Lyss, C. Kent Osborne, Martin Abeloff, Gabriel N. Hortobagyi, Daniel F. Hayes and Christine B. Ambrosone

LETTERS TO THE EDITOR

Chromosome 17 Polysomy without HER2 Amplification Does Not Predict Response to Lapatinib in Metastatic Breast Cancer—Letter

Cathy B. Moelans, Roel A. de Weger and Paul J. van Diest

Chromosome 17 Polysomy without HER2 Amplification Does Not Predict Response to Lapatinib in Metastatic Breast Cancer—Response

Leona Downey and Robert Livingston

Do Rectal Cancer Patients with PIK3CA Mutations Benefit from Preoperative Radiotherapy with Regard to Local Recurrences?

Youji He, Laura J. Van’t Veer, Marta Lopez-Yurda, Cornelis J.H. van de Velde and Corrie A.M. Marijnen

Clinical Usefulness of Microarrays for Cancer Prognosis in 2010—Letter

Serge Koscielny and Stefan Michiels

Statistical Evaluation of Clinical Usefulness of Microarrays for Cancer Prognosis Needs to be Placed in the Context of Clinical Reality—Response

Weida Tong and Xiaohui Fan

Acknowledgment to Reviewers
ABOUT THE COVER

Intracerebral xenograft initiated from the CD133+ glioblastoma stem-like cell line GBMJ1. At the initial signs of morbidity (94 days after implantation) a representative mouse was euthanized and the brain tumor prepared for histological analyses. This figure shows the immunofluorescent analyses of GFAP (red) and III tubulin (green) with nuclei counterstained with DAPI (blue) at 20x magnification. For details, see the article by Jamal and colleagues on page 6049 of this issue.